CKS2 Antibody (monoclonal) (M02)
Mouse monoclonal antibody raised against a full length recombinant CKS2.
- 产品详情
- 实验流程
- 背景知识
Application ![]()
| WB, E |
---|---|
Primary Accession | P33552 |
Other Accession | BC006458 |
Reactivity | Human |
Host | mouse |
Clonality | monoclonal |
Isotype | IgG2b Kappa |
Clone Names | 2G12-2A5 |
Calculated MW | 9860 Da |
Gene ID | 1164 |
---|---|
Other Names | Cyclin-dependent kinases regulatory subunit 2, CKS-2, CKS2 |
Target/Specificity | CKS2 (AAH06458, 1 a.a. ~ 79 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 E~~N/A |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | CKS2 Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
CKS2 protein binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function. The CKS2 mRNA is found to be expressed in different patterns through the cell cycle in HeLa cells, which reflects specialized role for the encoded protein.
REFERENCES
Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Shen DY, et al. Liver Int, 2010 Jan. PMID 19845855.Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer. Kang MA, et al. J Cancer Res Clin Oncol, 2009 Jun. PMID 19034516.Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Martinsson-Ahlz?n HS, et al. Mol Cell Biol, 2008 Sep. PMID 18625720.Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Lan Y, et al. Int J Cancer, 2008 Aug 1. PMID 18498131.Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. Bertheau P, et al. PLoS Med, 2007 Mar. PMID 17388661.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.